A kind of pharmaceutical composition, its preparation method and application

A technology of inhibitors and sediments, which is applied in the field of pharmacy, can solve the problems such as the prevention and treatment of neurodegenerative diseases without polysaccharides in leaves, and achieves the effects of remarkable medicinal effect, simple preparation process and inhibition of damage.

Active Publication Date: 2020-02-21
无锡紫杉药业股份有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In addition to paclitaxel and other small-molecule active substances in southern yew leaves, it has also been found that the active polysaccharides contained in southern yew leaves have activities such as improving immunity, protecting the liver, and anti-tumor, but there is no polysaccharide in leaves to prevent neurodegenerative diseases. report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition, its preparation method and application
  • A kind of pharmaceutical composition, its preparation method and application
  • A kind of pharmaceutical composition, its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1 Preparation of the pharmaceutical composition of the present invention

[0038] The extraction method of the southern yew extract comprises the following steps:

[0039]Take the southern yew leaves, add 10 times the amount of water to decoct three times, 2 hours each time, combine the decoction liquid, and cool to room temperature; add a precipitant to the decoction liquid until the volume ratio of the precipitant reaches 60%, and filter after standing Obtain a precipitate; mix the precipitate with water, centrifuge, deproteinize the supernatant with 15% trichloroacetic acid aqueous solution at 4°C, and centrifuge to obtain a supernatant; add a precipitant to the obtained supernatant, and filter to obtain a precipitate , washed with absolute ethanol and then dried in vacuum at 50° C. to obtain the southern yew leaf extract.

[0040] The extracted southern yew leaf extract is mixed with polyethylene glycol to make capsule medicine.

experiment example 2

[0041] Experimental example 2 Verification of inhibition of microglia activation

[0042] BV2 cells are mouse microglial cell lines;

[0043] Griess reagent: prepare 0.1% naphthalene ethylenediamine with distilled water, prepare 1% p-aminobenzenesulfonic acid with 5% phosphoric acid, mix the two in equal volume 1:1 before use;

[0044] Curcumin, formulated in DMSO;

[0045] Lipopolysaccharide LPS, prepared with sterile PBS, the final concentration is 300ng / mL;

[0046] Experimental method: (1) BV2 cells were cultured in DMEM-F12 medium containing 10% newborn bovine serum at 37°C, 5% CO 2 , 95% air, 100% relative humidity growth;

[0047] (2) BV2 cells in the logarithmic growth phase, after digesting and counting, were divided into 2×10 4 Inoculate each well into a 96-well plate, add the test substance 24 hours later, add LPS 1 hour later, the final concentration is 300ng / mL, continue to cultivate for 24 hours, and collect the medium supernatant;

[0048] (3) Take 100 μL o...

experiment example 3

[0054] Experimental example 3 Inhibition of neuroinflammation and neuron damage caused by LPS

[0055] Lipopolysaccharide, prepared with sterile PBS, the final concentration is 100ng / mL;

[0056] Curcumin formulated with DMSO;

[0057] experimental method:

[0058] (1) Establishment of the mixed culture system of primary hippocampal neurons / glial cells: The hippocampus was isolated under a dissecting microscope from SD rat embryos at 18 days pregnant, blown and beaten with a pipette until no tissue blocks could be seen, and filtered. Inoculated in 24-well plates;

[0059] (2) Cell administration treatment: After the above-mentioned primary cells were cultured for 7 days, they were co-incubated with the test substance respectively. After 3 hours, the stimulating agent LPS 100 ng / mL was added. After 5 hours, the culture medium was taken to measure IL-1β and TNF- α;

[0060] (3) After the cells were treated with drugs for 7 days, the medium was collected to detect LDH with LD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a drug, in particular to a pharmaceutical composition. The pharmaceutical composition comprises Taxus chinensis var. mairei leaf extracts and a pharmaceutically acceptable carrier, wherein the weight percentage of the Taxus chinensis var. mairei leaf extracts ranges from 0.1% to 99.9%. The pharmaceutical composition is natural in source, simple in preparation technology and low in toxicity to cells, the high effect of preventing and curing neurodegenerative disease is achieved, and a wide application prospect is achieved.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to a pharmaceutical composition, its preparation method and application. Background technique [0002] Neurodegenerative diseases (Neurodegenerative diseases, NDD) are a type of chronic central nervous system diseases based on the progressive degeneration and death of neurons, mainly affecting the cognitive function or motor function of patients, mainly including Alzheimer's disease (Alzheimer's disease, AD), Parkinson's disease (PD), Huntington's disease (Huntington disease), spinocerebellar ataxia (spinal cerebellar ataxias), amyotrophic lateral sclerosis (amyotrophic lateral sclerosis) and spinal cord muscle Atrophy (spinal muscular atrophy), etc. Although the clinical manifestations and lesion characteristics of these diseases are not the same, they all have the common features: progressive degeneration and necrosis of neurons, significant proliferation and activation of glial cells, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/13A61P25/28A61P25/16A61P25/00A61K127/00
CPCA61K36/13A61K2236/331A61K2236/39A61K2236/53
Inventor 李娟汤伟彬袁谱龙王莉佳
Owner 无锡紫杉药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products